海萝胶 → HCID 178509613，化合物

HRID 526461

反应方程式

HRID 526461 反应方程式
[CH:1]1[CH:2]=[CH:3][C:4]2N(O)N=[N:7][C:5]=2C=1.CCN=C=NCCCN(C)C.[C:22]([C:24]1[CH:29]=[CH:28][C:27]([C:30]2[CH:31]=[N:32][N:33]([C:36]3[CH:44]=[CH:43][C:39]([C:40]([OH:42])=O)=[CH:38][N:37]=3)[C:34]=2[OH:35])=[CH:26][CH:25]=1)#[N:23].CCN(C(C)C)C(C)C.C1(CCN)CC1.Cl>CN(C=O)C.CO.O>[C:22]([C:24]1[CH:29]=[CH:28][C:27]([C:30]2[CH:31]=[N:32][N:33]([C:36]3[CH:44]=[CH:43][C:39]([C:40]([NH:7][CH2:5][CH2:4][CH:3]4[CH2:2][CH2:1]4)=[O:42])=[CH:38][N:37]=3)[C:34]=2[OH:35])=[CH:26][CH:25]=1)#[N:23]

参与物

10

反应物 6

HCID 313海萝胶HCID 159081-(3-二甲基氨基丙基)-3-乙基碳二亚胺HCID 757711-羟基苯并三唑(HOBT)HCID 81531N,N-二异丙基乙胺HCID 102407612-环丙基乙胺HCID 178509615HCID 178509615，化合物

产物 1

HCID 178509613HCID 178509613，化合物

试剂、催化剂与溶剂 3

HCID 887(5BETA,17BETA)-17-羟基-17-(甲基-D3)-2'H-雄甾-2-烯并[3,2-C]吡唑-5'(1'H)-酮溶剂HCID 962聚[6-[4-(4-氰基苯基)苯氧基]己基甲基丙烯酸酯]溶剂HCID 6228N,N-二甲基甲酰胺溶剂

实验过程

Combined HOBT (66.2 mg, 0.490 mmol) and EDCI (94 mg, 0.490 mmol), a solution 6-(4-(4-cyanophenyl)-5-hydroxy-1H-pyrazol-1-yl)nicotinic acid (100 mg, 0.327 mmol, in DMF (1 mL)) and Hunig's base (169 mg, 1.306 mmol) in DMF (1 mL). Then 2-cyclopropylethanamine (41.7 mg, 0.490 mmol) was added and the reaction was stirred at ambient temperature for 14 h. The reaction mixture was diluted with MeOH (2 mL) and water (3 mL) and acidified to pH 4 using 1 N HCl to give a solid which were collected by filtration and recrystallized from MeOH to give the title compound as a solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 0.01-0.14 (m, 2H) 0.35-0.49 (m, 2H) 0.68-0.81 (m, 1H) 1.46 (q, J=7.07 Hz, 2H) 3.27-3.43 (m, 2H) 7.79 (d, J=8.59 Hz, 2H) 8.14 (d, J=6.32 Hz, 2H) 8.34-8.79 (m, 4H) 8.85-8.97 (m, 1H) 13.53 (br. s., 1H). MS m/z [M+H]+ 374.2.

后处理

  1. customto give a solid which
  2. filtrationwere collected by filtration
  3. customrecrystallized from MeOH

来源与证据

ORD记录
ord-be6b6c9d97b242b09f0364323edfe295
来源数据集
uspto-grants-2016_05
专利号
US09345713B2

关联笔记

加载中…